Oura Delays IPO, Citing Market Uncertainty Just Days Before Expected Nasdaq Debut

Oura, the Finnish-American maker of the Oura Ring, has postponed its initial public offering, citing market uncertainty, according to a filing made September 29, 2026. The delay comes just days before the company’s shares were expected to price during the week of September 28 and begin trading on the Nasdaq under the ticker OURA. Oura had set terms for a $2.1 billion raise, offering 50 million shares — 73% of them secondary — at a price range of $40 to $44, implying a fully diluted valuation of roughly $14.9 billion at the midpoint.

What Happened

Oura had announced its IPO terms on September 21, 2026, positioning the offering as one of the larger consumer-hardware debuts of the year. Cornerstone investors Eli Lilly and Dragoneer Investment Group had already committed $400 million, or roughly 19% of the deal, ahead of pricing. In its delay filing, Oura said it was postponing “in light of current market uncertainty” without naming a specific new listing date, and said it would continue to monitor conditions before rescheduling the roadshow’s final stretch.

The company, founded in Finland in 2013 and now headquartered in San Francisco, makes a finger-worn ring that tracks sleep, activity, stress, heart health, and women’s health metrics. Oura reported $1.4 billion in revenue for the twelve months ended June 30, 2026, split roughly 80% hardware and 20% subscription, with 5.0 million paid members as of that date — double the prior year — and a 12-month paid-member retention rate of approximately 85%. The ring is sold through about 8,400 retail doors across 56 markets.

Why It Matters

Oura’s offering had been closely watched as a test of investor appetite for consumer health-tech companies at multibillion-dollar valuations, following a string of confidential IPO filings throughout the year that signaled a maturing smart-ring market. A pulled or delayed pricing this close to the listing date suggests underwriters were seeing demand that did not support the $40–$44 range, or that broader volatility made bankers and the company unwilling to price into a shaky tape.

The delay also affects Oura’s early employees and venture backers, many of whom were counting on the offering’s largely secondary structure — 73% of the shares on offer were secondary, meaning existing shareholders, not the company, would have been the ones cashing out — to provide long-awaited liquidity. A postponement pushes that liquidity event further out and leaves open the question of whether Oura relists at a lower valuation range when market conditions stabilize.

Inside Oura’s Business

Oura’s growth over the past two years has been driven largely by its subscription model, which layers a monthly membership fee for detailed health insights on top of the one-time hardware purchase. The 100% year-over-year growth in paid members to 5.0 million, combined with 85% retention, has been central to the bull case bankers built the IPO pitch around, positioning Oura less as a hardware company and more as a recurring-revenue health-data platform.

$1.4 billion in trailing twelve-month revenue as of June 30, 2026
5.0 million paid subscription members, up 100% year over year
Approximately 85% twelve-month paid member retention
Sold through roughly 8,400 retail doors in 56 markets
Eli Lilly and Dragoneer had committed $400 million as cornerstone investors

Why the Market Backdrop Turned Difficult

Oura’s decision lands during a stretch of heightened volatility across equity and bond markets, with the 10-year Treasury yield recently touching its highest level since 2007 and broader indexes swinging on inflation concerns and shifting Federal Reserve rate expectations. Volatile markets typically make IPO bookrunners more conservative, since a weak debut-day trade can damage a company’s reputation with public investors for years. Several other companies that had lined up September and October listings have reportedly discussed similar timing adjustments as bankers wait for calmer conditions.

What Happens Next

Oura has not committed to a new listing date and said it will reassess as market conditions evolve. The company’s underlying business metrics remain unchanged by the delay, and Oura is not required to raise additional private funding in the interim, giving it flexibility to wait for a more favorable window rather than pricing at a discount. Analysts expect Oura to attempt to relist within the next two to three months if broader market volatility subsides.

Frequently Asked Questions

Why did Oura delay its IPO?

Oura cited current market uncertainty in its filing, delaying the offering just before shares were expected to price the week of September 28, 2026. The company gave no new target date.

What was Oura’s expected IPO valuation?

Oura had set terms for 50 million shares at $40 to $44 each, implying a fully diluted valuation of roughly $14.9 billion at the midpoint and a total raise of about $2.1 billion.

How big is Oura’s business today?

Oura reported $1.4 billion in revenue for the twelve months ended June 30, 2026, with 5.0 million paid subscription members and roughly 85% member retention, sold across about 8,400 retail doors in 56 markets.